Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone has shown promising efficacy in phase 2 trials. The VRd triplet regimen remains the standard of care for induction therapy for patients with newly diagnosed multiple myeloma.
